Cognitive outcomes
Executive function and the other trial
A favourable cognitive result deserves a close look. A separate trial with no significant neurocognitive benefit deserves equal space.
The older-adult trial
A 20-week controlled trial involving 152 older adults, including 66 with mild cognitive impairment, tested GHRH/tesamorelin. It reported improved executive function, a trend in verbal memory and increased IGF-1. The cognitive effects were comparable in the participants with mild cognitive impairment and the healthy participants.
I welcome the shift from a hormone measurement to a cognitive outcome in this experiment. Executive function was the favourable finding. Verbal memory was reported as a trend, which deserves to remain a trend when the result is described.
The reported population was older adults. A menopause-specific cognitive result would require a more specific study. The executive-function finding can be interesting on its own terms.
A different cognitive result in HIV
A Phase 2 trial in virally suppressed people with HIV and abdominal obesity found that tesamorelin reduced waist circumference compared with standard care, while the between-group improvement in neurocognitive function was not statistically significant.
The coexistence of those outcomes is instructive. A physical measurement changed without a significant neurocognitive benefit in that trial. I give the waist result credit for a physical change, with the cognitive question still requiring its own answer.
This was a different population from the older-adult trial. To me, the trials answer different questions and cannot cancel each other out. They leave a more specific question about which cognitive outcomes might change, and in whom.
The cognitive findings differ across these trials. Their populations and measured outcomes remain part of the account.
A menopause-specific cognitive question
The older-adult trial supports interest in its measured executive-function finding. The HIV trial limits a broader claim about reliable neurocognitive improvement. Neither article supplies a trial of menopause-related cognitive symptoms.
A future study specifying the symptom, the participants and the cognitive tasks could give a menopause claim the substance I am looking for. That remains a wish for future work.
A physiological dependency and a clinical outcome require separate explanations. A hormone response, an executive-function result and relief of a particular person's symptoms are distinct questions. I can welcome the executive-function result while leaving the symptom question open.